JIPOAd
JIPOAd
PARP
ESID
  • Users Online: 347
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2019  |  Volume : 2  |  Issue : 4  |  Page : 144-151

Review of immunogenomics and the role of tumor mutational burden as a biomarker for immunotherapy response


1 Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona, Spain
2 Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain
3 Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
4 Department of Investigational Cancer Therapeutics and Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence Address:
Dr. Javier Ros
Department of Medical Oncology, Vall d´Hebron University Hospital, Barcelona
Spain
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JIPO.JIPO_19_19

Get Permissions

Immune checkpoint inhibitors benefit a proportion of patients with cancer, but not all patients nor all histologies will respond to immunotherapy. Therefore, predictive biomarkers are needed. In this review, we outline the ways that lead to hypermutated tumors as well as the potential predictive role of tumor mutational burden (TMB). Findings in selected cancer types suggest that TMB may predict clinical response to immunotherapy, and recently even a prognostic role has been suggested for TMB. An association between high mutational load and clinical benefit was observed in various tumor types; however, it is unclear whether TMB is a strong predictive marker of clinical benefit across all cancers. For that reason, there are still several questions regarding the role of TMB as an immunotherapy biomarker, such as the best measurement technique, the most adequate cutoff, or even whether TMB will be useful for any kind of cancer. We have performed an extensive bibliography research using PubMed with keys words: immunotherapy, tumor mutational load, TMB, immunotherapy biomarkers, and immunotherapy response. In conclusion, TMB has been demonstrated to be a useful biomarker for immunotherapy selection across some cancer types; however, further validation studies are required.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed797    
    Printed25    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal